On Wednesday, TD (TSX:TD) Cowen adjusted its outlook on P3 Health Partners Inc (NASDAQ:PIII) shares, reducing the price target significantly to $0.25 from the previous $0.90. The firm has decided to maintain a Hold rating on the healthcare company's shares.
The revision comes in the wake of the company's third-quarter results for the year 2024. The analyst at TD Cowen has updated their financial model for P3 Health Partners to incorporate the latest quarterly performance. This model now includes the anticipation of a substantial $100 million capital raise in 2025, which is expected to support the company's ongoing operating losses.
In light of the financial update and the need for additional capital, adjustments have been made to the estimates for the years 2024 and 2025. These revised estimates have influenced the decision to lower the price target while keeping the stock's rating unchanged.
The analyst's commentary sheds light on the rationale behind the updated price target, stating, "We're updating our model to reflect 3Q24 results. Our model assumes PIII requires a $100m capital raise in 2025 to support continued operating losses. We adjust our model and revise our 2024/25 estimates, maintain our Hold rating and our price target moves to 25c from previous 90c."
Investors in P3 Health Partners Inc are now equipped with the latest forecasts from TD Cowen as they consider the future financial position of the company and its stock's potential trajectory.
In other recent news, P3 Health Partners (P3) reported a 26% year-over-year revenue increase to $362.1 million in its Q3 2024 earnings call, driven by a 22% growth in membership. However, an adjusted EBITDA loss of $71 million was reported, attributed to higher medical claims costs and retroactive adjustments.
The company has initiated over $130 million in strategic initiatives to improve EBITDA and cash flow, with benefits expected to start in Q4 2024. P3 is refining its approach to Medicare Advantage and value-based care, anticipating a favorable repricing cycle in 2025.
In addition, the company is optimizing its provider and payer networks to improve profitability. These are recent developments in the company's financial performance and strategic outlook. Management projects a less than $30 million quarterly EBITDA loss for 2024, with a total annual loss of $120 million. The company is exiting underperforming markets and contracts to focus on profitable segments, and there are no immediate capital raises planned for Q4 2023.
InvestingPro Insights
Recent data from InvestingPro paints a challenging picture for P3 Health Partners Inc (NASDAQ:PIII), aligning with TD Cowen's reduced price target. The company's market capitalization stands at a modest $75.44 million, reflecting investor concerns. InvestingPro Tips highlight that PIII is "quickly burning through cash" and "suffers from weak gross profit margins," which corroborates the analyst's expectation of continued operating losses and the need for a substantial capital raise.
The financial metrics support these observations, with a negative gross profit margin of -2.72% for the last twelve months as of Q3 2024. Additionally, the company's operating income margin sits at -16.69%, underscoring the operational challenges mentioned in the article.
InvestingPro Tips also indicate that the stock is "trading near 52-week low" and has "taken a big hit over the last week," with a one-week price total return of -15.61%. This recent performance trend aligns with the analyst's decision to lower the price target significantly.
For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for PIII, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.